Drug reference
Moderate to severe urinary frequency, urgency, and obstructive symptoms associated with benign prostatic hyperplasia when monotherapy ineffective Genito-urinary system ▶BY MOUTH ▶Adult (male): 1 tablet daily.
PDF page 851
DUE TO INTERACTIONS ▶Manufacturer advises max. 1 Vesomni ® tablet daily with concurrent use of potent inhibitors of CYP3A4; avoid concurrent use in patients who also have moderate hepatic impairment, severe renal impairment, are poor metabolisers of CYP2D6, or in patients also taking a potent inhibitor of CYP2D6.
PDF page 851
→Appendix 1: alpha blockers. solifenacin
PDF page 851
Manufacturer advises caution in moderate impairment; avoid in severe impairment (no information available). Dose adjustments Manufacturer advises max. 1 Vesomni ® tablet daily in moderate impairment.
PDF page 851
Dose adjustments Max. 1 Vesomni ® tablet daily if eGFR less than 30 mL/minute/1.73 m2.
PDF page 851
There can be variation in the licensing of different medicines containing the same drug. Modified-release tablet CAUTIONARY AND ADVISORY LABELS 3, 25 ▶Vesomni (Astellas Pharma Ltd) Tamsulosin hydrochloride 400 microgram, Solifenacin succinate 6 mg Vesomni 6mg/0.4mg modified-release tablets | 30 tablet P £27.62 DT = £27.62
PDF page 851
1 tablet daily.
First-line fragment. Read the complete Indications and Dose section above.
PDF page 851
